An open-label study of olanzapine in children and adolescents with schizophrenia

Journal of Psychiatric Practice

Volumn 13, Issue 2, 2007, Pages 86-96

  Quintana, Humberto ^a,c   Wilson II, Michael S ^a   Purnell, William ^a   Layman, Ann K ^a   Mercante, Don ^b  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF NEW ORLEANS   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescents; Antipsychotics; Children; Olanzapine; Open label trial; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; OLANZAPINE;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; BODY WEIGHT; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSPITAL ADMISSION; HUMAN; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA; SCHOOL CHILD; SEX RATIO; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHILD; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 34247145899     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000265765.25495.e0     Document Type: Article

References (82)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision (DSM-IV TR). Washington, DC, American Psychiatric Association; 2000.
2. Eggers C. Bunk D. The long term course of childhood-onset schizophrenia: A 42 year follow-up. Schizophr Bull 1997;23:105-17.
3. Lieberman JA, Perkins D. Belger A, et al. The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches. Bio Psychiatry 2001;50:884-97.
4. Yung AR, Phillips LJ, McGorry PD, et al. Predictions of psychosis: A step toward indicated prevention of schizophrenia. Br J Psychiatry Suppl 1998;172:14-20.
5. Green WH, Padron-Gayol M, Hardesty AS, et al. Schizophrenia with childhood onset: A phenomenological study of 38 cases. J Am Acad Child Adolesc Psychiatry 1992;31:968-76.
6. Kane JL, Leucht S, Carpenter D, Docherty JP. (2003) Expert consensus guidelines series: Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 64(Suppl 12): 5-19.
7. Findling R, Drury S, Jensen P, et al. AACAP official action: Summary of practice parameter for the use of antipsychotic medications in children and adolescents. Presented at American Academy of Child and Adolescent Psychiatry 2006.
8. Patel NC, Crisomon ML, Hoagowood K, et al. Trends in the use of typical and atypical antipsychotic in children and adolescents. J Am Acad Child Adolesc Psychiatry, 2005;44:548-56.
9. Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006;63:679-85.
10. Kinder Z, Mehler-Wex C, Rothenhofer S, et al. Atypical antipsychotics in child and adolescent psychiatry: Indications apart from schizophrenia. Jugendpsychiatr Psychother 2005;33:159-68.
11. Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. J Clin Psychiatry 2005;66(Suppl 7):29-40.
12. Bryden KE, Carrey NJ, Kutcher SP. Update and recommendations for the use of antipsychotics in early-onset psychoses. J Child Adolesc Psychopharmacol 2001;11:113-30.
13. Coghill D. Current issues in child and adolescent psychopharmacology. Part 2: Anxiety and obsessive-compulsive disorders, autism, Tourette's and schizophrenia. Advancements in Psychiatric Treatment 2003;9:289-99.
14. Green WH. Child and adolescent clinical psychopharmacology, 4th Edition. New York: Lippincott Williams and Williams; 2006.
15. Pappadopulos EA, Guelzow BA, Wong C, et al. A review of the growing evidence base for pediatric psychopharmacology. Child Psychiatry Clin North Am 2004;13:817-55.
16. Spencer EK, Kafantaris V, Padron-Gayol MV, et al. Haloperidol in schizophrenic children: Early findings from a study in progress. Psychopharmacol Bull 1992;28:183-6.
17. Pool D, Bloom W, Meielke DH, et al. A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Current Ther Res Clin Exp 1976;19:99-104.
18. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia: A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996;53:1090-97.
19. Kane J. Honigfeld G. Singer J. et al. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
20. Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004;29:133-45.
21. Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. Arch. Gen. Psychiatry 2006;63:721-30.
22. Research Units on Pediatric Psychopharmacology Autism Network (NIMH). Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 2005;162:1361-9.
23. Remschmidt H, Hennighhausen K, Clement HW, et al. Atypical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry 2000;9(Suppl 1):I9-19.
24. Pappadopulos E, Macintyre II JC, Crismon ML, et al. Treatment recommendations for the use of antipsychotic for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry 2003;42:145-61.
25. Kutcher S. Child and adolescent psychopharmacology. Philadelphia: WB Saunders; 1997.
26. Kutcher S. Practical clinical issues regarding child and adolescent psychopharmacology. Child Adolesc Psych Clin North Am 2000;9:245-60. Review.
27. FDA bulletin on clozapine (Clozaril). United States Food and Drug Administration; 1989.
28. Hamburger SD, Smith AK, Albus KE, et al. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996;53:1090-7.
29. Siefen G, Remschmidt H. Results of treatment with clozapine in schizophrenic adolescents. [German] Zeitschrift fur Kinderund Jugendpsychiatrie 1986;14:245-57.
30. Stahl SM. Essential psychopharmacology of antipsychotics and mood stabilizers. New York: Cambridge University Press; 2002.
31. Birmaher B, Baker R, Kapur S, et al. Clozapine for the treatment of adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 1992;31:160-4.
32. Armenteros JL, Witaker AH, Welikson M, et al. Risperidone in adolescents with schizophrenia: An open pilot. J Am Acad Child Adolesc Psychiatry 1997;36:694-700.
33. Zalmsman G, Carmon E, Martin A, et al. Effectiveness, safety and tolerability of risperidone in adolescents with schizophrenia: An open-label study. J. Child Adolesc Psychopharmacol 2003;61:319-27.
34. Borison RL, Pathiraja AP, Diamond BI, et al. Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1991;27:59-65.
35. Borison R. Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Janssen Clinical Research Report; 1992.
36. Quintana H, Keshavan M. Case study: Risperidone in children and adolescents with schizophrenia. Journal Am Acad Child Adolesc Psychiatry 1995;34:1292-6.
37. Mozes T, Ebert T, Michael SE, et al. An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. J Child Adolesc Psychopharmacol 2006;16:393-403.
38. Kefantaris V, Coletti DJ, Dicker R, et al. Adjunctive antipsychotic treatment of adolescents with bipolar psychosis. J Am Acad Child Adolesc Psychiatry 2001;40:1448-56.
39. Shaw JA, Lewis JE, Pascal S, et al. A study of quetiapine: Efficacy and tolerability in psychotic adolescents. J Clin Child Adolescent Psychopharmacology 2001;11:415-24.
40. McConville BJ, Arvanitis LA, Thyrum PT, et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open label trial in adolescents with psychotic disorders. J Child Psychiatry 2000;61:252-60.
41. McConville G, Carrero L, Swetlzer D, et al. Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: An open-label extension trial. J Child Adolesc Pyschopharmacol 2003;13:75-82.
42. Sallee FR, Kurlan CG, Goetz H, et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study. J Am Acad Child Adolesc Psychiatry 2000;39:292-9.
43. Meighen KG, Shelton HM, McDougle CJ. Ziprasidone treatment of two adolescents with psychosis. J Child Adolesc Psychopharmacol 2004;14:137-42.
44. Findling RL. Use of quetiapine in children and adolescents. J Clin Psychiatry 2002;63(Suppl 13):27-31.
45. McDougle CJ, Kern DL, Posey DJ. Case series: Use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002;41:921-7.
46. Toren P, Ratner S, Laor N, et al. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Safety 2004;27:1135-56.
47. Cheng-Shannon J, McGough JJ, McCracken JT. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2004;14:372-94.
48. Valicenti-McDermott MR, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 2006;16:549-60.
49. Rugino TA, Janvier YM. Aripiprazole in children and adolescents: Clinical experience. J Child Neurol 2005;20:603-10.
50. Masi G, Mucci M, Pari C. Children with schizophrenia: Clinical picture and pharmacological treatment. CNS Drugs 2006;20:841-66.
51. McConville BJ, Sorter MT. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry 2004;65(Suppl 6):20-29.
52. Stigler KA, Potenza MN, McDougle CJ. Tolerability profile of atypical antipsychotics in children and adolescents. Paediatric Drugs 2001;3:927-42.
53. Findling RI, Kusumaker V, Moshang T, et al. Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 2003;64:1362-9.
54. Clark C, Burg MR. Diabetes mellitus associated with atypical antipsychotic medications. Diabetes Technol Ther 2003;5:669-83.
55. Stigler KA, Potenza MN, Posey DJ, et al. Weight gain associated with atypical antipsychotic use in children and adolescents: Prevalence, clinical relevance, and management. Paediatr Drugs 2004;6:33-44.
56. Green AI, Patel JK, Goisman RM, et al. Weight gain from novel antipsychotic drugs: Need for action. Gen Hosp Psychiatry 2000;22:224-35.
57. Allison DB, Casey DE. Antipsychotic-induced weight gain: A review of the literature. J Clin Psychiatry 2001;62(Suppl 7):22-32.
58. Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: Comparative prospective study. J Am Acad Child Adolesc Psychiatry 2002;41:337-43.
59. Frazier JA, Bieerman J, Tohen M, et al. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2001;11:239-50.
60. Bostic JQ, Prince J, Frazier J, et al. Pediatric psychopharmacology update. Psychiatric Times 2003 September:86-95.
61. Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry 1997;58(Suppl 10):13-7.
62. Grothe DR, Calis KA, Jacobsen L, et al. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. J Clin Psychopharmacol 2000;20:220-5.
63. Alfaro CL, Wudarsky M, Nicolson R, et al. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol 2002;12:83-91.
64. Overall JE, Pfefferbaum B. The Brief Psychiatric Rating Scale for Children. Psychopharmacol Bull 1982;18:10-16.
65. Lambert M, Conus P, Lambert T, et al. Pharmacotherapy of first-episode psychosis. Expert Opin Pharmacother 2003;4:717-50.
66. Mozes T, Greenberg Y, Spivak B, et al. Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: An open-label study. J Child Adolesc Psychopharmacol 2003;13:311-7.
67. Findling RL, McNamara NK, Youngstrom EA, et al. A prospective, open-label trial of olanzapine in adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2003;42:170-5.
68. Ross RG, Novins D, Farley GK, et al. A 1-year open label trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharm 2003;13:301-9.
69. Sholevar EH, Baron DA, Hardie TL. Treatment of childhoodonset schizophrenia with olanzapine. J Child Adolesc Psychopharmacol 2000;10:69-78.
70. van Bruggen J, Tijssen J, Dingemans P, et al. Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. Int Clin Psychopharmacol 2003;18:341-6.
71. Gothelf D, Falk B, Singer P, et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 2002;159:1055-7.
72. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003;28(Suppl 1):83-96.
73. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997;36:980-8.
74. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Report 1962;10:799-812.
75. Fields JH, Grochowski S, Lindenmayer JP, et al. Assessing positive and negative symptoms in children and adolescents. Am J Psychiatry 1994;151:249-53.
76. Guy W. Clinical Global Impression Scale. ECDEU assessment manual for psychopharmacology - Revised (DHEW Publ No ADM 76-338). NIMH Psychopharmacology Research Branch; 1976:218-22.
77. Shaffer D, Gould MS, Brasic J, et al. Children's Global Assessment Scale [CGAS]. Arch Gen Psychiatry 1983;40:1228-31.
78. Guy W. Abnormal Involuntary Movement Scale. ECDEU assessment manual for psychopharmacology (DHEW Publication ADM 76-338). Rockville, MD: US Department of Health, Education, and Welfare; 1976:534-37.
79. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-83.
80. Wirshing DA, Pierre JM, Eyeler J, et al. Risperidone-associated new-onset diabetes. Biol Psychiatry 2001;50:148-9.
81. McGlashan TH, Zipursky RB, Perkins D, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790-9.
82. Campbell M, Palij M. Documentation of demographic data and family history of psychiatric illness. Psychopharmacol Bull 1985;21:719-33.